BioGaia is an innovative Swedish health care company specializing in probiotics. With over 30 years of experience in microbiome research, BioGaia develops, markets, and sells a range of probiotic products aimed at enhancing gut, oral, immune, and bone health. Their offerings are anchored in scientifically well-documented bacterial strains from the Lactobacillus reuteri species, which are known for their distinct health benefits. BioGaia's commitment to quality and research is reflected in the efficacy of their products. The class B shares of BioGaia are listed on the Mid Cap list of the Nordic Exchange in Stockholm, emphasizing the company's strong position in the health care market.